You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
濟川藥業(600566.SH)半年度淨利潤升14.38%至9.64億元
格隆匯 08-23 17:04

格隆匯8月23日丨濟川藥業(600566.SH)發佈2019年半年度報告,實現營業收入39.07億元,同比增長2.71%;歸屬於上市公司股東的淨利潤9.64億元,同比增長14.38%;歸屬於上市公司股東的扣除非經常性損益的淨利潤9.11億元,同比增長10.49%;基本每股收益1.18元。

研發方面。報告期內,公司圍繞“兒科、口腔、呼吸、消化、婦科”五大領域,持續優化研發體系,不斷擴充技術研發隊伍,加強高端、特色仿製藥的項目立項及推進。同時,公司繼續推進現有中藥品種的二次開發,大力推進品種引進,不斷豐富公司產品羣。

生產方面報告期內,公司完成了注射劑二車間(大容量注射劑、小容量注射劑)的GMP認證現場檢查工作;3號液體樓作為目前國內規模最大的中藥口服液智能化車間正式投產,口服液年產能7.2億支,有力地支撐了公司戰略目標的推進。公司經營產品質量穩定,無藥品質量事故發生,無不合格產品被公告等情況。

銷售方面。報告期內,公司產品蒲地藍消炎口服液銷售承擔了較大的壓力。公司制定了“調整、整合、開發、優化”的方針,在加強醫院、OTC藥店、基層醫療機構開發力度的同時,對已開拓的渠道資源進行了梳理,進一步落實資源拓深舉措。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account